drugset / Trial / NCT03201562

A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia

NCT03201562

Phase 2 Completed 58 enrolled LENZ Therapeutics, Inc
RandomizedCrossoverTriple-blindTreatment

Summary

To evaluate the safety and efficacy of PRX-100 compared with aceclidine alone and vehicle in the treatment of early to moderate presbyopia.

Timeline

Start
2017-04-30
Primary completion
2018-05-20
Completion
2018-05-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aceclidine Small molecule
Subject tropicamide Small molecule

Indications